<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03703791</url>
  </required_header>
  <id_info>
    <org_study_id>ARC009</org_study_id>
    <secondary_id>2018-000326-58</secondary_id>
    <nct_id>NCT03703791</nct_id>
  </id_info>
  <brief_title>Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents</brief_title>
  <official_title>Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adolescents: Real World, Open Label, Quality of Life Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aimmune Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aimmune Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the HRQOL of AR101 characterized oral desensitization immunotherapy (CODIT™) in
      combination with standard of care (peanut avoidance, education) versus standard of care alone
      in peanut-allergic subjects aged 4 to 17 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3b, randomized, open label, European study of the HRQOL of AR101 in
      combination with standard of care compared with standard of care alone in approximately 200
      peanut-allergic subjects aged 4 to 17 years, inclusive.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor terminated study; no impact on overall benefit risk evaluation of AR101
  </why_stopped>
  <start_date type="Actual">October 24, 2018</start_date>
  <completion_date type="Actual">November 23, 2018</completion_date>
  <primary_completion_date type="Actual">November 23, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>18 months</time_frame>
    <description>To assess the health-related quality of life (HRQL) of peanut allergic subjects aged 4-17 years receiving AR101 in combination with standard of care versus standard of care alone for approximately 18 months, using self- and proxy-reported age appropriate versions of the Food Allergy Quality of Life Questionnaire (FAQLQ). The FAQLQ total and domain scores range from 1-7 with higher scores indicative of worse HRQL; with the total score being the average of the domain scores. The domains include Emotional Impact, Social and Dietary Restrictions, Food Anxiety, Allergen Avoidance, and Risk of Accidental Exposure.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Peanut Allergy</condition>
  <arm_group>
    <arm_group_label>Group 1 (AR101 Treatment + standard of care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects receiving AR101 treatment will have 3 consecutive AR101 dosing periods before exiting (completing) the study: initial dose escalation, up dosing, and maintenance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (Standard of Care Treatment)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects receiving standard of care alone will have approximately 18 months of observation before study exit, with an OLFC (open label food challenge) approximately 12 months after randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AR101</intervention_name>
    <description>AR101 powder</description>
    <arm_group_label>Group 1 (AR101 Treatment + standard of care)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 4 through 17 years

          -  History of physician diagnosed IgE mediated peanut allergy with characteristic signs
             and symptoms

          -  Positive SPT for peanut

          -  Positive serum IgE to peanut

          -  Written informed consent from the subject's parent/guardian

          -  Written assent from the subject as appropriate

          -  Use of effective birth control by sexually active female subjects of childbearing
             potential

        Exclusion Criteria:

          -  Uncertain clinical diagnosis of peanut allergy

          -  History of severe or life threatening episode of anaphylaxis or anaphylactic shock
             within 60 days of screening

          -  Severe persistent asthma or uncontrolled mild or moderate asthma

          -  History of eosinophilic esophagitis, other eosinophilic gastrointestinal disease,
             severe gastroesophageal reflux disease, symptoms of dysphagia or recurrent
             gastrointestinal symptoms of undiagnosed etiology

          -  History of a mast cell disorder, including mastocytosis, urticarial pigmentosa, and
             hereditary or idiopathic angioedema

          -  History of cardiovascular disease, including uncontrolled or inadequately controlled
             hypertension

          -  History of chronic disease (other than asthma, atopic dermatitis, or allergic
             rhinitis) that is, or is at significant risk of becoming, unstable or requiring a
             change in chronic therapeutic regimen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruth Bateson</last_name>
    <role>Study Chair</role>
    <affiliation>Aimmune Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>8916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporacio Sanitaria Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>8208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Severo Ochoa</name>
      <address>
        <city>Leganes</city>
        <state>Madrid</state>
        <zip>28911</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron - PPDS</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Universitario Niño Jesus</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28032</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://www.aimmune.com/medical-information-request-form/</url>
    <description>Click to request more information about this study.</description>
  </link>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>October 9, 2018</study_first_submitted>
  <study_first_submitted_qc>October 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2018</study_first_posted>
  <last_update_submitted>December 13, 2018</last_update_submitted>
  <last_update_submitted_qc>December 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AR101</keyword>
  <keyword>Characterized Peanut Allergen CPNA</keyword>
  <keyword>(Characterized Peanut Allergen) OIT</keyword>
  <keyword>Peanut Allergy</keyword>
  <keyword>Allergy</keyword>
  <keyword>Peanut-Allergic Children</keyword>
  <keyword>Peanut-Allergic Adolescents</keyword>
  <keyword>Desensitization</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>OIT (oral immunotherapy)</keyword>
  <keyword>CODIT (TM) Characterized Oral Desensitization Immunotherapy (TM)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Peanut Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

